Cold atmospheric plasma therapy for the treatment of verrucae vulgares of the hands and feet in children: a prospective, randomized, placebo-controlled clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00038710

Enrollment

Registered

2026-01-02

Start date

2026-05-19

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B07

Interventions

Group 1: Treatment with cold plasma

basic therapy with salicylic acid patches. Before each cold plasma therapy session, the wart is curetted. The examination and treatment of patients will be carried out for a maximum of 8 consecutive w

from week 4 to week 8, once per week (visit 7-11). Data will be collected using pre-designed questionnaires as well as micro- and macroscopic photographic images. Four weeks after healing or after the

basic therapy with salicylic acid patches. Before each placebo therapy session, the wart is curetted. The examination and treatment of patients will be carried out for a maximum of 8 consecutive weeks

Eligibility

Sex/Gender

All

Age

5 Years to 17 Years

Inclusion criteria

Inclusion criteria: -Presence of verrucae vulgares on the hands and/or feet -Diagnosis confirmed by dermoscopy -Written informed consent from the patient and both legal guardians -Basic therapy with Guttaplast® -Wart present for at least 6 months and previously unsuccessfully treated with at least one method

Exclusion criteria

Exclusion criteria: -Allergy or intolerance to salicylic acid -renal insufficiency (as a relative contraindication for salicylic acid use) -Systemic therapy with mtx or sulfonylureas (potential interactions with salicylic acid) -Active implants (e.g., pacemaker, ICD) -Neurological disorders -Severe mental disorders -Hypersensitive reactions to electrical stimuli -Severe asthma -Pregnant patients -Hyperthyroidism

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the complete healing of the wart. This will be assessed during the follow-up visits (twice weekly in the first 3 weeks, Visits 1–6, and thereafter weekly, Visits 7–11) and at the final examination (4 weeks after healing or at the latest after the last follow-up visit, Visit 11). The study period is planned to be approximately 10 months. Data will be collected through photographic documentation, including dermoscopic microimages, as well as questionnaires at each visit/examination.	—

Measure

Time frame

The primary endpoint is the complete healing of the wart. This will be assessed during the follow-up visits (twice weekly in the first 3 weeks, Visits 1–6, and thereafter weekly, Visits 7–11) and at the final examination (4 weeks after healing or at the latest after the last follow-up visit, Visit 11). The study period is planned to be approximately 10 months. Data will be collected through photographic documentation, including dermoscopic microimages, as well as questionnaires at each visit/examination.

—

Secondary

Measure	Time frame
Partial wart clearance rate (more than 50%)	—

Countries

Germany

Contacts

Public ContactOzan Haase

Hautpartner - Gemeinschaftspraxis Dres. Krengel/Mrowka/Haase

haase@hautpartner.de+49 451 81551

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026